Inmune Bio Announces $4.2M Australian R&D Cash Rebate

What Happened
Inmune Bio, Inc. (INMB) announced in an 8-K filed July 31, 2026 that it received a research and development cash rebate from Australia of approximately $4.2 million on July 30, 2026. The company issued a press release about the receipt of the rebate, which is included as an exhibit to the filing.

Key Details

• Received approximately $4.2 million in an Australian R&D cash rebate on July 30, 2026.
• Announcement disclosed via Form 8-K filed July 31, 2026; press release attached as Exhibit 99.1.
• The item was reported under Item 8.01 ("Other Events") of the 8-K.

Why It Matters
This cash rebate provides near-term non-operating cash inflow that can help fund Inmune Bio’s research and development activities or general corporate needs without diluting shareholders. While not revenue or earnings, the $4.2M cash receipt improves the company’s liquidity position and may reduce near-term financing pressure. Investors should view this as a one-time cash benefit tied to R&D activity in Australia, not recurring operating revenue.